Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3589-3597

  Wolff, Antonio C ^a   Donehower, Ross C ^a   Carducci, M Katherine ^a   Carducci, Michael A ^a   Brahmer, Julie R ^a   Zabelina, Yelena ^a   Bradley, Matthews O ^b   Anthony, Forrest H ^b   Swindell, Charles S ^b   Witman, Philip A ^b   Webb, Nigel L ^b   Baker, Sharyn D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Protarga Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; DOCOSAHEXANOIC ACID PLUS PACLITAXEL; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COVALENT BOND; DIARRHEA; DOSE RESPONSE; DRUG ACTIVATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; PACLITAXEL; TAXOIDS; TIME FACTORS;

EID: 12444330550     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol) [published erratum appears in N. Engl. J. Med., 333: 75, 1995]. N. Engl. J. Med., 332: 1004-1014, 1995.
2. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., and McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93: 2325-2327, 1971.
3. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
4. Donehower, R. C. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Oncologist, 1: 240-243, 1996.
5. Donehower, R. C., Rowinsky, E. K., Grochow, L. B., Longnecker, S. M., and Ettinger, D. S. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat. Rep., 71: 1171-1177, 1987.
6. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111: 273-279, 1989.
7. Sauer, L. A., and Dauchy, R. T. Uptake of plasma lipids by tissue-isolated hepatomas 7288CTC and 7777 in vivo. Br. J. Cancer, 66: 290-296, 1992.
8. Sauer, L. A., and Dauchy, R. T. Tumour-host metabolic interrelationships. Biochem. Soc. Trans., 18: 80-82, 1990.
9. Sauer, L. A., Stayman, J. W., III, and Dauchy, R. T. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res., 42: 4090-4097, 1982.
10. Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L., Horwitz, S. B., and Swindell, C. S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res., 7: 3229-3238, 2001.
11. Sparreboom, A., Wolff, A. C., Verweij, J., Zabelina, Y., van Zomeren, D. M., McIntire, G. L., Swindell, C. S., Donehower, R. C., and Baker, S. D. Disposition of DHA-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin. Cancer Res., 9: 151-159, 2003.
12. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
13. de Bono, J. S., Stephenson, J., Jr., Baker, S. D., Hidalgo, M., Patnaik, A., Hammond, L. A., Weiss, G., Goetz, A., Siu, L., Simmons, C., Jolivet, J., and Rowinsky, E. K. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol., 20: 96-109, 2002.
14. D'Argenio, D. Z., and Schumitzky, A, A program package for simulation and parameter estimation in pharmacokinetics. Comput. Prog. Biomed., 9: 115-1134, 1979.
15. Yamaoka, K., Nakagawa, T., and Uno, T. Akaike information criterion. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
16. Baker, S. D., Diasio, R. B., O'Reilly, S., Lucas, V. S., Khor, S. P., Sartorius, S. E., Donehower, R. C., Grochow, L. B., Spector, T., Hohneker, J. A., and Rowinsky, E. K. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J. Clin. Oncol., 18: 915-926, 2000.
17. Seidman, A. D., Hochhauser, D., Gollub, M., Edelman, B., Yao, T. J., Hudis, C. A., Francis, P., Fennelly, D., Gilewski, T. A., Moynahan, M. E., Currie, V., Baselga, J., Tong, W., O'Donaghue, M., Salvaggio, R., Auguste, L., Spriggs, D., and Norton, L. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol., 14: 1877-1884, 1996.
18. Smith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S. J., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Baez, L., DeFusco P. A., Davila, E., Tipping, S. J., Bearden, J. D., and Thirlwell, M. P. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol., 17: 3403-3411, 1999.
19. Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., and Beijnen, J. H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated pro-drug of paclitaxel. Anticancer Drugs, 12: 315-3237 2001.
20. Todd, R., Boddy, A. V., Verrill, M., Sludden, J., Griffin, M, J., Elliott, S., Fishwick, K., Robson, I., Cassidy. J., Main, M., Bisset, D., Brannan, M., and Calvert, A. H. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate. Clin. Cancer Res., 7 (Suppl.): 3676s, 2001.
21. Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V., ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., and Beijnen, J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2127-2135, 1993.